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1 Authors contributed equally to the work.Osteolytic bone diseases including osteoporosis are commonly accompanied with enhanced osteo-
clast formation and bone resorption. Naringin, a natural occurring ﬂavonoid has been found to pro-
tect against retinoic acid-induced osteoporosis and improve bone quality in rats. Here, we showed
that naringin perturbs osteoclast formation and bone resorption by inhibiting RANK-mediated NF-
jB and ERK signaling. Naringin suppressed gene expression of key osteoclast marker genes. Narin-
gin was found to inhibit RANKL-induced activation of NF-jB by suppressing RANKL-mediated IjB-a
degradation. In addition, naringin inhibited RANKL-induced phosphorylation of ERK. This study
identiﬁes naringin as an inhibitor for osteoclast formation and bone resorption, and provides evi-
dence that natural compounds such as naringin might be beneﬁcial as an alternative medicine
for the prevention and treatment of osteolysis.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Enhanced osteoclast formation and bone resorption is an under-
lining mechanism of osteolytic bone diseases including osteoporo-
sis, Paget’s disease of bone, bone metastatic diseases, erosive
arthritis, aseptic bone loosening and non-union. Understanding
the molecular processes by which osteoclasts are formed and acti-
vated, and identifying the pharmacological intervention to perturb
these processes might contribute to the prevention and treatment
of osteoporosis.
Osteoclasts are the principal cells responsible for bone resorp-
tion and the main targets of current anti-resorptive drugs. The
receptor activator of nuclear factor-kappa B (NF-jB) (RANK) ligandchemical Societies. Published by E
; ERK, extracellular receptor
olony stimulatory factor; NF-
RANKL, receptor activator of
nscriptase-polymerase chain
gy and Laboratory Medicine,
Centre, 1st Floor M Block,(RANKL) is a key cytokine obligatory for osteoclast formation, acti-
vation and survival [1,2]. The interaction of RANKL with RANK re-
sults in a cascade of intracellular events including NF-jB, AKT,
MAPKs, NFAT, ionic calcium and calcium/calmodulin-dependent
kinase. Among these pathways, NF-jB signaling has been shown
to play an essential role in osteoclastogenesis [3,4].
Naringin, a natural occurring ﬂavonoid is the major active com-
ponent found in grapefruit and other related citrus. It inhibits dihy-
dropyridine oxidation and aﬂatoxin B1 activation in human liver
microsomes, and might have cancer chemoprevention properties
[5]. It also protects against radiation-induced chromosomal dam-
age in mouse bone marrow cells [6,7], and lomeﬂoxacin-induced
genomic instability [8]. Interestingly, naringin has been shown to
protect against retinoic acid-induced osteoporosis in Sprague Daw-
ley rats [9] and improve bone quality in orchidectomized male rats
[10]. However, the cellular and molecular mechanism by which
naringin offers protective effects against bone loss is not clear.
In search of natural compounds that exhibit pharmacologically
inhibitory effects on osteoclasts, we have found that naringin
inhibits osteoclast formation and bone resorption. Furthermore,
we demonstrated that naringin inhibits RANKL-induced NF-jB
activation, IjB-a degradation and ERK phosphorylation, by and
large correlating its inhibitory effect on osteoclastogenesis and
bone resorption.lsevier B.V. All rights reserved.
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2.1. Media and reagents
Alpha modiﬁed of Eagles Medium (a-MEM) and fetal bovine
serum (FBS) was purchased from TRACE (Sydney, Australia). Narin-
gin (>95% purity) was purchased commercially from Sigma–Al-
drich (Sydney, Australia) and dissolved in Dimethyl sulfoxide
(DMSO). Luciferase assay systemwas obtained from Promega (Syd-
ney, Australia). Recombinant GST-rRANKL protein was expressed
and puriﬁed as previously described [2].
2.2. Cell culture
RAW264.7 cells were obtained from the American Type Culture
Collection (Rockville, MD, USA). RAW264.7 cells were grown as per
American Type Culture Collection guidelines in a-MEM supple-
mented with 10% heat inactivated FBS, 2 mM L-glutamine and
100 U/ml penicillin/streptomycin (complete a-MEM). Primary
bone marrow macrophages were grown in a-MEM supplemented
with 10% heat inactivated FBS, 2 mM L-glutamine and 100 U/ml
penicillin/streptomycin with the addition of macrophage-colony
stimulating factor (M-CSF, 25 ng/ml). All cell cultures were main-
tained in 5% CO2 at 37 C.
2.3. In vitro osteoclastogenesis assay
Osteoclast-like cells were generated using an established pro-
osteoclastic system as previously described [11]. In brief, freshly
isolated bone marrow macrophages (BMM) from C57/BL6 mice
were cultured with M-CSF (25 ng/ml) for the ﬁrst 3 days. BMM
were then seeded onto a 96 well plate (8  103 cells/well) with
complete a-MEM containing M-CSF (25 ng/ml) and GST-rRANKL
(100 ng/ml). Medium and naringin was replaced every 2–3 days
and after 7 days, cultures were ﬁxed with 4% paraformaldehyde
in phosphate buffered saline (PBS) for 10 min at room temperature
and then washed four times with PBS. Fixed cells were stained for
tartrate-resistant acid phosphatase (TRACP) using the DiagnosticFig. 1. Naringin inhibits RANKL-induced osteoclastogenesis in BMM cultures. (A) Chemic
M-CSF and RANKL with different concentrations of naringin. Seven days post-culture, cell
effect of naringin on the formation of TRACP(+) OCL cells (⁄⁄⁄P-value < 0.001). (C) Light mi
osteoclast formation. A representative example of more than three experiments is showAcid Phosphatase kit (Sigma) according to the manufacturer’s
instructions and TRACP positive multinucleated cells (>3 nuclei)
were scored as osteoclast-like (OCLs) cells.
2.4. Immunoﬂuorescent staining and confocal microscope
For immunoﬂuorescence studies, 1  104 RAW264.7 cells were
plated onto a 6-well plate pre-seeded with ﬁve coverslips. After
overnight of incubation, cells were stimulated with RANKL
(100 ng/ml) for 5 days to induce osteoclast formation in the ab-
sence or presence of naringin (0.1 and 0.5 mM). Cells were then
washed twice with 1  PBS, ﬁxed for 15 mins at room temperature
with 4% paraformaldehyde in 1  PBS (pH 7.4) and then washed
extensively with 1  PBS. Cells were permeabilized in 1  PBS con-
taining 0.1% Triton X-100, washed twice in 1  PBS containing 0.2%
BSA (0.2% BSA–PBS). Cells were then stained for 45 min at room
temperature with Alexa Fluor 488 phallotoxin (Molecular Probes,
Inc., Eugene, OR) diluted 1:500 in 0.2% BSA–PBS. Cells were washed
in 0.2% BSA–PBS and PBS as above, counter stained for 3 min at
room temperature with DAPI (Santa Cruz Biotechnology, Inc., CA)
and mounted for confocal microscopy (MRC-1000; Bio-Rad, CA).
2.5. Apoptosis assay
Apoptosis assays were performed as per manufacturer’s
instruction (BD-Pharmigen, NSW, Australia) and as previously de-
scribed [14]. In brief, RAW264.7 cells were seeded (1  106 cells
per well) into a 6-well plate containing 2 ml of complete medium.
Cells were allowed to adhere overnight at 37 C before exposure to
varying doses of naringin for a further 24 h. Cells were harvested
and resuspended in 0.5 ml of Annexin V Binding Buffer. Microfuge
tubes containing resuspended cells (100 ll), Annexin V-PE (5 ll)
and 7-Amino-Actinomycin (7-AAD) (5 ll) were gently vortexed
and then incubated for 15 min at room temperature in the dark.
Binding buffer (400 ll) was added to each tube and within 1 h,
10 000 cells were analyzed by ﬂow cytometry (Becton Dickinson
FACSCalibur). Results were expressed as a percentage of apoptotic
cells within the population.al structure of naringin. (B) Freshly isolated BMMs were cultured in the presence of
s were ﬁxed with 4% paraformadehyde followed by TRACP staining. Dose-dependent
croscope images depicting the dose-dependent effect of naringin on RANKL-induced
n.
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Human giant cell tumour (GCT) of bone samples was freshly
isolated from patients who had undergone surgery at the Sir
Charles Gairdner Hospital (Nedlands, WA, Australia). Tumour tis-
sues were ﬁnely chopped in complete a-MEM and the resultant
cell suspension was passed through a 100 lm nylon cell strainer
(BD Bioscience, MA, USA). Approximately 200 OCL cells were
seeded onto bovine bone slices in the presence and absence of
naringin. After culturing for 24 h at 37 C, bovine bone slices were
incubated for 2 h in 2 M NaOH and OCL cells were removed by
mechanical agitation and sonication. Resorption pits were visual-
ized under Philips XL30 scanning electron microscope (S.E.M.)
and the percentage of bone surface area resorbed quantiﬁed using
Scion Image software (Scion Cooperation, National Institutes of
Health) [12,13].
2.7. RNA isolation and Reverse transcription (RT)-PCR
Total RNA was isolated with a commercially available RNA
extraction kit (Qiagen, Victoria, Australia). For RT-PCR, single
stranded cDNA was prepared from 2 lg of total RNA isolated using
reverse transcriptase with oligo-dT primer [15]. All PCR was car-
ried out using 2 ll of each cDNA using cycling parameters 94 C,
45 s; 58 C, 45 s; and 72 C, 45 s for 30 cycles (except for calcitoninFig. 2. Naringin decreases the size of OCL cells. RAW264.7 cells were cultured in the pr
After 5 days of culture, cells were ﬁxed with 4% paraformaldehyde and double stained
Confocal images of OCL cells left untreated (a–c), treated with 0.1 mM naringin (d–f) and 0
average of ﬁve randomly selected ﬁelds (400) were measured and graphed (⁄⁄⁄P-valuereceptor, TRACP and DC-STAMP whose annealing temperature was
60 C) with primers designed against the following mouse se-
quences: Cathepsin K (forward: GGG AGA AAA ACC TGA AG; re-
verse: ATT CTG GGG ACT CAG AGA GC), calcitonin receptor:
(forward: TGG TTG AGG TTG TGC CCA; reverse: CTC GTG GGT
TTG CCT CAT C), TRACP: (forward: TGT GGC CAT CTT TAT GCT; re-
verse: GTC ATT TCT TTG GGG CTT), V-ATPase d2: (forward: ATG
CTT GAG ACT GCA GAG; reverse: TTA TAA AAT TGG AAT GTA
GCT), DC-STAMP: (forward: CTT GCA ACC TAA GGG CAA AG; re-
verse: TCA ACA GCT CTG TCG TGA CC) and acidic ribosomal phos-
phoprotein (36B4), which served as an internal control: (forward:
TCA TTG TGG GAG CAG ACA; reverse: TCA ACA GCT CTG TCG
TGA CC) [12]. Fifteen microliters of each PCR product were sepa-
rated on a 1.5% agarose gel containing ethidium bromide and visu-
alized and photographed under ultra-violet light.
2.8. NF-jB luciferase reporter gene assay
To examine NF-jB activation, RAW264.7 cells stably transfected
with a luciferase reporter gene (p-NF-jB-TA-Luc) [16], were plated
in 24-well plates at a density of 1  105 cells/well and pre-treated
with naringin for 1 h, followed by GST-rRANKL (100 ng/ml)
stimulation for 8 h. Cells were harvested and luciferase activity
measured using the Promega Luciferase Assay System according
to manufacturer’s instructions (Promega).esence of RANKL with naringin in a six-well plate pre-seeded with glass coverslips.
with DAPI (nuclear staining) and phallotoxins (F-actin structure) antibodies. (A)
.5 mM naringin (g–i). (B) Total cell spread area and nuclear area of OCL cells from an
< 0.001).
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Proteins were separated by SDS–PAGE gel and electroblotted
onto nitrocellulose membranes (BioRad). Membranes were
blocked with 5% (w/v) skim milk powder (SMP) in TBST (10 mM
Tris, pH 7.5, 150 mM NaCl, 0.1% {v/v} Tween 20) and then probed
with primary antibodies to phosphorylated forms of ERK, IjB-a
and a-tubulin (Santa Cruz Biotechnology Inc.) in 1% (w/v) SMP in
TBST. After three washes with 1  TBS, membranes were incubated
with HRP-conjugated secondary antibodies diluted 1/5000 in 1%
(w/v) SMP in TBST. The membranes were then developed using
the ECL system (Amersham Pharmacia Biotech, Sydney, Australia).
2.10. Statistical analyses
Data presented were representative results from a set of three
independent experiments or the mean ± S.E.M. of those experi-
ments. Student’s t test was used to analyze statistical signiﬁcance
between a tested group with its respective control group. A P-value
of <0.05 was considered to be statistically signiﬁcant.
3. Results
3.1. Naringin suppresses RANKL-induced osteoclastogenesis
To examine the effect of naringin on RANKL-induced osteo-
clastogenesis, we incubated RANKL-treated BMM with various
concentrations of naringin and evaluated the formation of OCL
cells. TRACP positive cells with more than 3 nuclei were scored
as OCL cells. BMM cultured in the presence of M-CSF and RANKL
form multinucleated TRACP-positive OCL cells (Fig. 1B). Addition
of naringin into BMM cultures showed dose-dependent inhibition
of osteoclast formation as measured by the TRACP positive multi-
nucleated cells. Notably, OCL cells in cultures that were treated
with naringin were smaller than control OCL cells (Fig. 1C). There
was no observable cell loss (cell detachment) observed at concen-Fig. 3. Naringin dose dependently induces apoptosis of RAW264.7 cells. (A) RAW264.7 c
with Annexin V-PE and 7-AAD and 10 000 cells were subjected to analysis by ﬂow cy
percentage of the total cells population displaying apoptosis (⁄⁄⁄P-value < 0.001, compartrations tested up to 1 mM. To further evaluate the morphological
changes, we examined the effect of naringin on the size of OCL cells
during RANKL-induced osteoclast formation via the use of confocal
microscopy. OCL cells in the presence or absence of naringin treat-
ment were double-stained with phallotoxins and DAPI to allow for
visualization of the cytoskeleton and nuclei respectively (Fig. 2A(a–
c)). In comparison, naringin treated OCL cells were smaller in size
and had fewer numbers of nuclei than the untreated control
(Fig. 2A(d–i) and B). Naringin alone without the presence of RANKL
did not stimulate osteoclast development (data not shown). These
data thus suggest that naringin abrogates RANKL-induced osteo-
clastogenesis. To exclude the possibility that the observed inhibi-
tory effect of naringin on osteoclastogenesis might be due to
apoptosis, apoptosis assays and FACS analysis were carried out
on osteoclast precursor cells stained with both Annexin V-PE and
7-AAD (Fig. 3A). Rates of apoptosis were low in RAW264.7 cells left
treated or untreated with up to 1 mM of naringin. However, at con-
centrations of naringin greater than 5 mM, rates of apoptosis sig-
niﬁcantly increased, with more than 55% of cells undergoing
apoptosis (Fig. 3B). These results suggest that the inhibition of
osteoclastogenesis by naringin at doses up to 1 mM is not due to
the induction of apoptosis.
3.2. Naringin attenuates osteoclastic bone resorption
To test the effect of naringin on osteoclastic bone resorption,
equal number of Giant cell tumor of bone (GCT)-derived osteo-
clasts was seeded onto bovine bone slices and, after attachment
naringin was added to the culture. Bone surfaces were retrieved
after incubation for a further 24 h, processed for scanning electron
microscopy, visualised and scored for bone resorption, as described
in the methods. Treatment of cultures with naringin attenuated
osteoclastic bone resorption (Fig. 4). Note that treatment of narin-
gin resulted in very shallower resorption pits or reduced pit areas
as compared to untreated control (Fig. 4A and B). Noteworthy, this
impairment of bone resorption did not reﬂect cell death of OCLells treated with varying doses of naringin for 24hrs were harvested, double-stained
tometry. (B) Results, representative of three independent experiments, show the
ed to the untreated controls).
Fig. 4. Naringin abrogates bone resorption and induced apoptosis. Equal number of OCL cells (derived from patients presenting with GCT of bone) was seeded onto bovine
bone slices and allowed to adhere to the surface before the addition of naringin at varying doses (0, 0.5 and 1 mM) for 24 h. (A) Representative S.E.M. images of bone
resorption pits are shown. (B) The total areas of resorption pits were measured under S.E.M. and are presented graphically (⁄⁄⁄P-value < 0.001). (C) Total number of TRACP
positive OCL cells per bone slice.
E.S.M. Ang et al. / FEBS Letters 585 (2011) 2755–2762 2759cells as no signiﬁcant differences in the total number of TRACP-po-
sitive cells per bone slice were observed after the treatment of
naringin (Fig. 4C). Taken together, these experiments conclude that
naringin inhibits osteoclastic bone resorption.
3.3. Naringin suppresses RANKL-induced gene expression
To further elucidate the role of naringin on osteoclast differen-
tiation, we examined its effect on the gene expression of cathepsin
k, calcitonin receptor, TRACP, dendritic cell-speciﬁc transmem-
brane protein (DC-STAMP), V-ATPase d2 (d2), all marker genes of
osteoclasts. BMM cultures were treated with M-CSF (25 ng/ml)
and GST-rRANKL (100 ng/ml) in the absence or presence of
naringin for 5 days followed by with total RNA isolation. Semi-
quantitative RT-PCR was performed using primers for cathepsin
k, calcitonin receptor, TRACP, DC-STAMP, d2 and 36B4. Naringin
reduced the gene expression of osteoclastic gene markers cathep-
sin k, calcitonin receptor and TRACP in a dose dependent manner
during osteoclastogenesis (Fig. 5A and B), consistent with its inhib-
itory effects on osteoclastogenesis and bone resorption. To add to
this, naringin also suppressed osteoclast fusion gene (DC-STAMP
and d2) expression.
3.4. Naringin suppresses RANKL-induced activation of NF-jB by
preventing IjB-a degradation
To measure the inhibitory effect of naringin on NF-jB transcrip-
tional activity, RAW264.7 cells that had been stably transfected
with an NF-jB luciferase reporter construct [16] were stimulated
with RANKL in the presence and absence of naringin. Twenty-four
hours of RANKL (100 ng/ml) treatment alone, an increase in lucif-
erase activity was observed. Pre-treatment (1 h) of cells with
naringin prior to RANKL stimulation (8 h) resulted in a signiﬁcant
dose-dependent reduction in NF-jB luciferase activity (Fig. 6A).Surprisingly, naringin alone increased the NF-jB luciferase activity
in a dose dependent manner, indicating a role for naringin in bi-
phasic modulation of NF-jB signaling pathways.
To add to this, we investigated the effect of naringin on RANKL-
induced. IjB-a degradation was observed at 10 and 20 min post-
RANKL-stimulation with maximum degradation observed at
20 min as compared to unstimulated controls. The addition of
naringin resulted in a suppression of IjB-a degradation, as seen
at a concentration (0.5 and 1 mM) as well as time (10 and
20 min) dependent manner (Fig 6B). Interestingly, in the absence
of RANKL, the basal levels of IjB-a were increased by naringin at
1 h and 20 min post-treatment (0.5 and 1.0 mM).
3.5. Naringin inhibits RANKL-induced ERK phosphorylation
To further explore pathways by which naringin regulates osteo-
clast differentiation and function, the effect of naringin on RANKL-
induced ERK phosphorylation was examined in RAW264.7 cells
that had been exposed to naringin. Western blot analyses demon-
strated ERK phosphorylation after 15 mins of RANKL treatment,
and naringin exhibited an inhibitory effect on RANKL-induced
ERK phosphorylation (Fig. 7). In comparison, in the presence of
naringin, the basal level of ERK1/2 was increased in the absence
of RANKL stimulation.
4. Discussion
Animal studies have found that naringin can protect against
retinoic acid-induced osteoporosis in Sprague Dawley rats [9]
and improve bone quality in orchidectomized male rats [10]. Inter-
estingly, in this study, we showed that naringin inhibits osteoclast
formation and bone resorption via the suppression of RANKL-
induced activation of NF-jB and ERK. These data provide the
mechanistic explanation, at least in part for the protective effect
Fig. 5. Naringin dose-dependently reduces RANKL-induced gene expression (A, B). BMM cells were seeded onto six-well plates in the presence and absence of RANKL (100 ng/
ml) for 5 days with various doses of naringin (0, 0.5 and 1 mM). Total RNA was isolated and cDNA was synthesized using 2 lg of total RNA with oligo-dT. PCR ampliﬁcation
was performed using speciﬁc primers for cathepsin K, calcitonin receptor, TRACP, DC-STAMP, d2 and 36B4 (house-keeping) genes. (A) PCR products were separated on 1.5%
agarose gels. (B) The relative levels of gene expression are shown as the ratios of cathepsin k, calcitonin receptor, TRACP, DC-STAMP, d2 to 36B4 genes.
Fig. 6. Naringin suppresses RANKL-induced NF-jB activation, prevents IjB-a degradation. (A) RAW264.7 cells stably transfected with the 3kB-Luc-SV40 reporter gene were
pre-treated with varying doses of naringin for 1 h followed by RANKL (100 ng/ml) stimulation. Luciferase activity in the lysates was determined after 8 h of RANKL
stimulation. Each bar represents the mean ± SE from triplicate wells (⁄P-value < 0.05, ⁄⁄P-value < 0.01). (B) RAW264.7 cells were pre-treated with naringin for 1 h prior to
RANKL (100 ng/ml) stimulation for 0, 10 and 20 min. Proteins extracted from whole cell were separated and transferred onto nitrocellulose membranes, which were then
blocked and probed sequentially with antibodies to IjB-a and b-actin. Bands were visualized by ECL and semi-quantiﬁed by densitometry. Results shown are a representation
of one of three experiments performed. The levels of IjB-a proteins are shown as a ratio to b-actin.
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Fig. 7. Naringin inhibits RANKL-induced ERK phosphorylation. RAW264.7 cells were pre-treated with naringin for 1 h prior to RANKL (100 ng/ml) stimulation for 0 and 15
mins. Proteins extracted fromwhole cell were separated and transferred onto nitrocellulose membranes, which were then blocked and probed sequentially with antibodies to
phosphorylated ERK and b-actin. Bands were visualized by ECL and semi-quantiﬁed by densitometry. Results shown are a representation of one of three experiments
performed. The levels of phosphorylated ERK proteins are shown as a ratio to b-actin.
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molecular mechanism by which this natural compound inhibits
osteoclasts might provide invaluable information for the treatment
of osteolysis.
During RANKL-induced osteoclastogenesis, RANKL binds with
RANK resulting in the recruitment of TRAF6 and the activation of
NF-jB and MEK kinases [17–19]. NF-jB signaling has been shown
to play an important role in osteoclastogenesis [3]. NF-kappaB
p50/ and p52/ double knockout mice exhibit severe osteope-
trosis due to failure of osteoclast formation [20,21]. Therefore sup-
pression of NF-jB activation would play an important role in
osteoclast formation. Interestingly, in the present study, naringin
was shown to reduce RANKL-induced NF-jB-activity, simulta-
neously with inhibition of RANKL-induced differentiation of osteo-
clasts. Intriguingly, naringin appeared to increase the basal level of
NF-jB activity in the absence of RANKL stimulation (Fig. 6A). How-
ever, naringin alone also appeared to increase the IjB-a levels, 1 h
and 20 min post-treatment in a time-dependent manner (Fig. 6B).
This could represent the resynthesis of IjB-a following the activa-
tion of NF-jB accompanied with the initial IjB-a degradation. The
MEK/ERK also regulates the differentiation of RAW264.7 cells into
osteoclast-like cells [22–24]. We have demonstrated that naringin
prevents RANKL-induced phosphorylation of ERK, outcomes which
might also affect osteoclast differentiation and survival. The effect
of naringin on MEK/ERK has not been documented in other cell
types, representing novel data that requires further investigation.
Interestingly, in line with our ﬁndings from this study, naringin
has been shown to inhibit TNF-induced reactive oxygen intermedi-
ate (ROI) generation and NF-jB, indicating that naringin might
serve as a potent drug for anti-inﬂammatory and antioxidant ther-
apy [25]. These multiple effects of naringin could further explain
the underlining mechanism of action of naringin in osteoclasto-
genesis and bone resorption.
Previous studies have shown that naringin suppresses TNF pro-
duction induced by LPS [26,27]. Interestingly, naringin, at a similar
concentration used in this study, also suppressed LPS induced pro-
duction of nitric oxide (NO) and the expression of inﬂammatory
gene products, including inducible NO synthase (iNOS), TNF-alpha,
inducible cyclooxygenase (COX-2) and interleukin-6 (IL-6) via the
inhibition of NF-jB [28]. Since iNOS, COX-2, TNF-a and IL-6 are po-
sitive regulators for osteoclastogenesis [29,30], and the expression
of a battery of these genes is induced by NF-jB [31], the inhibition
of NF-jB by naringin could result in the suppression of the expres-
sion of these genes and might contribute to its inhibitory effect on
osteoclast formation and bone resorption. Understanding the phar-
macological mechanisms of naringin in bone biology will be
important in developing an effective approach to prevent and treat
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